Supplementary Figure S9 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma

Sean R. Corcoran; James D. Phelan; Jaewoo Choi; Galina Shevchenko; Rachel E. Fenner; Xin Yu; Sebastian Scheich; Tony Hsiao; Vivian M. Morris; Evangelia K. Papachristou; Kamal Kishore; Clive S. D’Santos; Yanlong Ji; Stefania Pittaluga; George W. Wright; Henning Urlaub; Kuan‐Ting Pan; Thomas Oellerich; Jagan Muppidi; Daniel J. Hodson; Louis M. Staudt

doi:10.1158/2159-8290.26935082.v1

Key Points

Mutation of CD79A and CD79B glycosylated residues does not alter sensitivity to MMAE in preclinical diffuse large B-cell lymphoma models.
Assessment of diffuse large B-cell lymphoma reveals consistent cellular responsiveness to MMAE regardless of engineered CD79A or CD79B alterations.
Highlights that polatuzumab vedotin sensitivity is independent of these specific glycosylation sites; cell model, further preclinical study needed.

Implication

Preclinical analysis reveals that mutating CD79A and CD79B glycosylation sites does not alter MMAE sensitivity in diffuse large B-cell lymphoma, indicating payload response remains intact.

Abstract

Mutation of CD79A and CD79B glycosylated residues does not alter sensitivity to MMAE

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Corcoran et al. (2024) studied this question.

synapsesocial.com/papers/68e5968ab6db64358753130b https://doi.org/10.1158/2159-8290.26935082.v1

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure S9 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S9 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers